Finally, we sought to demonstrate in vivo that HER3-specific polyclonal anti-HER3 serum alone, when transferred to tumor-bearing animals, retards growth of both HER2 therapy-resistant tumors and TNBC. This evidence concerns the gene ERBB3 and neoplasm.